CCM
MLYS icon

Coldstream Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Coldstream Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-779
Closed -$12.4K – 2434
2025
Q1 		$12.4K Buy
+779
New +$8.96K ﹤0.01% 2296

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Coldstream Capital Management's MLYS Position: Q2 2025 in Review

Coldstream Capital Management sold out of Mineralys Therapeutics (MLYS) in Q2 2025, closing a stake of 779 shares — an estimated $12.4K sold.

Coldstream Capital Management first reported a position in MLYS in Q1 2025 and held it in 1 quarter. The position peaked at $12.4K in Q1 2025. 165 funds tracked by Wall St. Rank hold MLYS as of Q2 2025.

  • Coldstream Capital Management reported no remaining Mineralys Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 779 Mineralys Therapeutics shares in Q2 2025, an estimated $12.4K.
  • Coldstream Capital Management first reported a position in Mineralys Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Mineralys Therapeutics position peaked at $12.4K in Q1 2025.
  • 165 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.